In 2010, the therapeutic cancer vaccine market witnessed several key milestones. Dendreon’s Provenge (sipuleucel-T) became the first product to reach the market; gaining long-awaited FDA approval for metastatic hormone-refractory prostate cancer.
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
Despite intensive R&D efforts over the past two decades, lung cancer is the leading cause of cancer-related mortality worldwide with median overall survival firmly remaining below one year. Over one million new cases of lung cancer were diagnosed worldwide in 2008. According to Arrowhead’s report Lung Cancer Therapeutics Market Outlook and Pipeline Analysis, in 2009, lung cancer incidence will exceed over 464,000 cases in the seven major pharmaceutical markets.
The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail the markets for colorectal cancer, prostate cancer, lung cancer, breast cancer, leukemia and non-Hodgkin’s lymphoma.
In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to Spectra’s expert cancer report.
The stakes are high in the global oncology market, currently estimated at US$42 billion. Hundreds of novel and next-generation anticancer products are in research and development; however, not all are destined for market success and an estimated 37% or more key preclinical candidates may fail due to poor clinical performance despite increasing investment.